- Home
- ANVS vs CCIF Comparison
ANVS vs CCIF Comparison
Compare ANVS & CCIF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ANVS | CCIF |
|---|---|---|
| Founded | 2008 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance/Investors Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 50.4M | 48.7M |
| IPO Year | 2019 | 2011 |
Fundamental Metrics
Financial Performance| Metric | ANVS | CCIF |
|---|---|---|
| Price | $1.15 | $2.28 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $10.50 | N/A |
| AVG Volume (30 Days) | ★ 812.0K | 133.1K |
| Earning Date | 11-11-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 25.90% |
| EPS Growth | ★ 39.39 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.04 | $2.20 |
| 52 Week High | $5.50 | $5.49 |
Technical Indicators
Market Signals| Indicator | ANVS | CCIF |
|---|---|---|
| Relative Strength Index (RSI) | 39.09 | 36.12 |
| Support Level | $1.14 | $2.20 |
| Resistance Level | $1.43 | $2.91 |
| Average True Range (ATR) | 0.08 | 0.11 |
| MACD | 0.01 | -0.00 |
| Stochastic Oscillator | 8.47 | 28.57 |
Price Performance
Historical ComparisonAbout ANVS Annovis Bio Inc.
Annovis Bio Inc, a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company's flagship candidate, buntanetap, is in clinical trials for the treatment of Alzheimer's disease, Parkinson's disease, and Lewy body dementia. It also develops ANVS405, which is in phase 2 and 3 clinical trials for the treatment of traumatic brain injury and/or stroke; and ANVS301, which finished phase 1 clinical trial developed to increase cognitive capability in later stages of alzheimer's disease and dementia.
About CCIF Carlyle Credit Income Fund Shares of Beneficial Interest
Carlyle Credit Income Fund is a non-diversified, closed-end management investment company. The Fund's primary investment objective is to generate current income, with a secondary objective to generate capital appreciation. The Fund seeks to achieve its investment objective by investing predominantly in equity and junior debt tranches of collateralized loan obligations, that are collateralized by a portfolio consisting mainly of below-investment-grade U.S. senior secured loans with a large number of distinct underlying borrowers across various industry sectors.